SG Americas Securities LLC Acquires 18,053 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

SG Americas Securities LLC raised its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 35.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,973 shares of the company’s stock after buying an additional 18,053 shares during the period. SG Americas Securities LLC’s holdings in Lineage Cell Therapeutics were worth $35,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Lineage Cell Therapeutics by 2.3% in the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after purchasing an additional 83,274 shares in the last quarter. Barclays PLC grew its stake in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after acquiring an additional 159,924 shares in the last quarter. State Street Corp lifted its position in Lineage Cell Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Lineage Cell Therapeutics by 13.9% during the third quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock valued at $613,000 after purchasing an additional 82,864 shares during the last quarter. Finally, MAI Capital Management lifted its position in Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock valued at $1,516,000 after purchasing an additional 35,907 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Stock Up 1.4 %

Shares of LCTX opened at $0.69 on Friday. The firm has a market cap of $153.17 million, a PE ratio of -5.79 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.48 and a 12-month high of $1.61.

Analysts Set New Price Targets

Several brokerages recently commented on LCTX. D. Boral Capital decreased their target price on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday. Finally, Maxim Group dropped their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.